"Fundamentally Wrong": Less Than 5% Of Cancer Patients Get Access To Clinical Trials
Long R&D time-line is "unacceptable," says Memorial Sloan Kettering cancer specialist Bob Li
Source: forbes.com
Page 7 - Project Orbis News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Project Orbis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Project Orbis Today - Breaking & Trending Today
What's Next For President Biden's Cancer Moonshot?
Targets include better screening and preventable cancers, says Deputy Assistant to President for the Cancer Moonshot Dr. Danielle Carnival
Source: forbes.com
FDA Grants Xtandi Priority Review for Certain Patients with Prostate Cancer
The FDA has granted a priority review for the evaluation of Xtandi as a treatment for patients with non-metastatic castration-sensitive prostate cancer.
Source: curetoday.com
Pfizer's ELREXFIO™ Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma – India Education | Latest Education News | Global Educational News
Pfizer Inc. (NYSE:PFE) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval to ELREXFIO™ (elranatamab-bcmm) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have recei
Source: indiaeducationdiary.in
Pfizer's Elrexfio tries to challenge Janssen in RRMM with FDA approval
The FDA accelerated approval for the bispecific antibody is based on the results from a single-arm Phase II study in multiple myeloma.
Source: pharmaceutical-technology.com